Circulating immune cell populations related to primary breast cancer, surgical removal, and radiotherapy revealed by flow cytometry analysis

Table 1 Clinical-pathological data of breast cancer patients included in the study

Patient number	Age	ER (%)	PR (%)	HER2 (+/−)	Ki67 (%)	Grade	Tumor size	LN mets	Anti-hormonal therapy
1	62	95	70	−	5	1	pT1b	pN1a	−
2	58	95	95	−	10	2	T1b	N0	−
3	50	100	100	+	5	1	pT1	pN0	Tamoxifen
4	73	95	2	−	25	2	pT2	pN1a	−
5	49	90	80	−	10	2	T1b	pN0	Tamoxifen
6	69	100	100	−	15	2	pT1a	pN0	Tamoxifen
7	53	95	60	−	10	2	pT1c	pN0	Letrozole
8	73	100	0	−	20	na	pT1c	pN0	Tamoxifen
9	67	90	80	−	5	1	pT1b	pN0	Tamoxifen
10	66	100	100	−	5	2	pT1c	pN0	Letrozole
11	64	95	80	−	10	1	pT1b	pN0	Letrozole
12	61	80	100	−	10	2	pT1b	pN0	Anastrozole
13	43	95	95	−	10	2	pT1c	pN0	Tamoxifen

Patient’s demographics, tumor subtype, grade, stage (pT and pN), and anti-hormonal treatment after conservative surgery. ER (%), estrogen receptor expression in percent; PR (%), progesterone receptor expression in percent; HER2 (±), overexpression of HER-2; Ki67 (%), fraction of cancer cells positive for Ki67 expression

ISSN: 1465-542X